Antithrombin nanoparticles inhibit stent thrombosis in ex vivo static and flow models

Journal of Vascular Surgery

Volumn 64, Issue 5, 2016, Pages 1459-1467

  Palekar, Rohun U ^a   Vemuri, Chandu ^b   Marsh, Jon N ^b   Arif, Batool ^b   Wickline, Samuel A ^a,b  

^a WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRO PHENYLALANYLPROLYLARGINYL CHLOROMETHYL KETONE; FLUOROCARBON; NANOPARTICLE; PERFLUOROCARBON NANOPARTICLE; THROMBIN; UNCLASSIFIED DRUG; VORAPAXAR; ANTITHROMBIN; DRUG CARRIER; PEPTIDE CHLOROMETHYL KETONE; PHENYLALANYL-PROLYL-ARGININE-CHLOROMETHYL KETONE; STAINLESS STEEL;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; CORONARY STENT; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; STENT THROMBOSIS; THROMBOCYTE POOR PLASMA; THROMBOCYTE RICH PLASMA; ADVERSE EFFECTS; BLOOD; BLOOD FLOW VELOCITY; CELL CULTURE; CHEMISTRY; DEVICES; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; STENT; SURFACE PROPERTY; THROMBOSIS; TIME FACTOR;

AMINO ACID CHLOROMETHYL KETONES; ANTITHROMBINS; BLOOD COAGULATION; BLOOD FLOW VELOCITY; CELLS, CULTURED; DRUG CARRIERS; ENDOTHELIAL CELLS; FLUOROCARBONS; HUMANS; NANOPARTICLES; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; STAINLESS STEEL; STENTS; SURFACE PROPERTIES; THROMBOSIS; TIME FACTORS;

EID: 84951335846     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2015.08.086     Document Type: Article

References (23)

1. 1 Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Blaha, M.J., et al. AHA statistical update. Circulation 129 (2013), e28–e92.
2. 2 Mauri, L., Kereiakes, D.J., Yeh, R.W., Driscoll-Shempp, P., Cutlip, D.E., Steg, P.G., et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
3. 3 Cutlip, D.E., Baim, D.S., Ho, K.K., Popma, J.J., Lansky, A.J., Cohen, D.J., et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103 (2001), 1967–1971.
4. 4 Ong, D.S., Jang, I.K., Causes, assessment, and treatment of stent thrombosis-intravascular imaging insights. Nat Rev Cardiol 12 (2015), 325–336.
5. 5 Thukkani, A.K., Kinlay, S., Endovascular intervention for peripheral artery disease. Circ Res 116 (2015), 1599–1613.
6. 6 Berger, P.B., Bhatt, D.L., Fuster, V., Steg, P.G., Fox, K.A., Shao, M., et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 121 (2010), 2575–2583.
7. 7 Myerson, J., He, L., Lanza, G., Tollefsen, D., Wickline, S., Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis. J Thromb Haemost 9 (2011), 1292–1300.
8. 8 Myerson, J.W., He, L., Allen, J.S., Williams, T., Lanza, G., Tollefsen, D., et al. Thrombin-inhibiting nanoparticles rapidly constitute versatile and detectable anticlotting surfaces. Nanotechnology, 25, 2014, 395101.
9. 9 Kaiser, B., Pharmacology of synthetic thrombin inhibitors of the tripeptide type. Cardiovasc Drug Rev 10 (1992), 71–87.
10. 10 Myerson, J.W., Thrombin-inhibiting perfluorocarbon nanoparticles: a new class of therapeutic for acute thrombosis treatment and diagnosis. Dissertation: Washington University in St. Louis. 2014, ProQuest/UMI, Ann Arbor Publication No. 9781303826375.
11. 11 Palekar, R.U., Myerson, J.W., Schlesinger, P.H., Sadler, J.E., Pan, H., Wickline, S.A., Thrombin-targeted liposomes establish a sustained localized anticlotting barrier against acute thrombosis. Mol Pharm 10 (2013), 4168–4175.
12. 12 Magnani, G., Bonaca, M.P., Braunwald, E., Dalby, A.J., Fox, K.A., Murphy, S.A., et al. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc, 4, 2015, e001505.
13. 13 Chatterjee, S., Sharma, A., Mukherjee, D., PAR-1 antagonists: current state of evidence. J Thromb Thrombolysis 35 (2012), 1–9.
14. 14 Zhang, K., Liu, T., Li, J.A., Chen, J.Y., Wang, J., Huang, N., Surface modification of implanted cardiovascular metal stents: from antithrombosis and antirestenosis to endothelialization. J Biomed Mater Res A 102 (2014), 588–609.
15. 15 Borrelli, V., Sterpetti, A.V., Coluccia, P., Randone, B., Cavallaro, A., Santoro D'Angelo, L., et al. Bimodal concentration-dependent effect of thrombin on endothelial cell proliferation and growth factor release in culture. J Surg Res 100 (2001), 154–160.
16. 16 Wang, H.S., Li, F., Runge, M.S., Chaikof, E.L., Endothelial cells exhibit differential chemokinetic and mitogenic responsiveness to α-thrombin. J Surg Res 68 (1997), 139–144.
17. 17 Wang, B., Pearson, T., Manning, G., Donnelly, R., In vitro study of thrombin on tubule formation and regulators of angiogenesis. Clin Appl Thromb Hemost 16 (2010), 674–678.
18. 18 Borissoff, J.I., Heeneman, S., Kilinç, E., Kassák, P., van Oerle, R., Winckers, K., et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 122 (2010), 821–830.
19. 19 Jagadeesha, D.K., Takapoo, M., Banfi, B., Bhalla, R.C., Miller, F.J., Nox1 transactivation of epidermal growth factor receptor promotes N-cadherin shedding and smooth muscle cell migration. Cardiovasc Res 93 (2012), 406–413.
20. 20 Victor, V.M., Rocha, M., Solá, E., Bañuls, C., Garcia-Malpartida, K., Hernández-Mijares, A., Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des 15 (2009), 2988–3002.
21. 21 van Aalst, J.A., Zhang, D.-M., Miyazaki, K., Colles, S.M., Fox, P.L., Graham, L.M., Role of reactive oxygen species in inhibition of endothelial cell migration by oxidized low-density lipoprotein. J Vasc Surg 40 (2004), 1208–1215.
22. 22 Wöhrle, J., Brodie, B., Witzenbichler, B., Dudek, D., Kornowski, R., Metzger, C., et al. Impact of bivalirudin and paclitaxel-eluting stents on outcomes in patients undergoing primary percutaneous coronary intervention of the left anterior descending artery. Am J Cardiol 112 (2013), 753–760.
23. 23 Chan, Y.C., Cheng, S.W., Drug-eluting stents and balloons in peripheral arterial disease: evidence so far. Int J Clin Pract 65 (2011), 664–668.